Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment publishing date : 2021 - 12 - 09 save search
FMC Corporation signs agreements with Corteva Agriscience to provide growers seed treatment insecticides
Published: 2021-12-09 (Crawled : 23:00) - prnewswire.com
FMC | $57.82 1.55% 0.0% 1.3M
|
Process Industries
|
| O: -0.25%
H: 0.0%
C: 0.0%
treatment
Aurinia Announces Positive Topline Results From the AURORA 2 Continuation Study of LUPKYNIS™ (voclosporin) for the Treatment of Adults With Active Lupus Nephritis (LN)
Published: 2021-12-09 (Crawled : 20:00) - biospace.com/
AUPH | $5.01 4.16% 3.99% 1.6M
|
Health Technology
|
| O: 3.7%
H: 2.55%
C: -2.92%
treatment lupkynis topline results positive results topline lupus
Denovo Biopharma and QIAGEN partner to develop companion diagnostic test for the treatment of Diffuse Large B-Cell Lymphoma (DLBCL)
Published: 2021-12-09 (Crawled : 19:00) - biospace.com/
QGEN | $40.0 1.34% 0.0% 1.1M
|
Health Technology
|
| O: 0.82%
H: 0.29%
C: -1.35%
QGEN | $40.0 1.34% 0.0% 1.1M
|
Health Technology
|
| O: 0.82%
H: 0.29%
C: -1.35%
diagnostic treatment biopharma test t-cell
Cyclo Therapeutics Appoints Caroline Hastings, M.D. as Global Principal Investigator for Ongoing TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease
Published: 2021-12-09 (Crawled : 14:30) - biospace.com/
CYTH | $1.19 -0.83% -0.84% 57K
|
Professional, Scientific, and T...
|
| O: -1.49%
H: 3.9%
C: -2.6%
trappsol treatment ema ongoing therapeutics disease
INmune Bio, Inc. Announces Key Breast Cancer Treatment Resistance Data to be Presented at the 2021 San Antonio Breast Cancer Symposium
Published: 2021-12-09 (Crawled : 14:30) - globenewswire.com
INMB | $8.33 -5.34% -5.64% 69K
|
Health Technology
|
| O: -0.88%
H: 2.56%
C: -0.08%
treatment cancer breast cancer symposium
Vir Biotechnology Announces Initiation of Phase 2 Clinical Trial Evaluating VIR-2218, Selgantolimod and Nivolumab for the Treatment of Chronic Hepatitis B Virus Infection
Published: 2021-12-09 (Crawled : 14:30) - biospace.com/
VIR | $7.96 0.0% 1.1M
|
Health Technology
|
| O: -1.69%
H: 6.48%
C: 2.62%
vir-2218 treatment phase 2 hepatitis technology trial biotech infection iot infections chronic hepatitis b nivolumab
Mustang Bio to Host Key Opinion Leader Webinar on MB-106, a Potential Treatment for B-Cell Non Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
Published: 2021-12-09 (Crawled : 14:00) - globenewswire.com
MBIO | $0.3451 -6.98% -7.51% 130K
|
Health Technology
|
| O: 2.88%
H: 1.87%
C: -3.27%
FBIO | $1.765 -2.49% -2.55% 190K
|
Health Technology
|
| O: 4.85%
H: 0.0%
C: 0.0%
mb-106 treatment leukemia potential lymphomas t-cell
Acer Therapeutics Announces ACER-801 IND Clearance for the Treatment of Induced Vasomotor Symptoms
Published: 2021-12-09 (Crawled : 14:00) - globenewswire.com
ACER | $0.9 -3.61% 420K
|
Health Technology
|
| O: 10.22%
H: 1.36%
C: -2.71%
acer-801 treatment clearance therapeutics
Cytokinetics Announces Receipt of Breakthrough Therapy Designation from FDA for AficamtenFDA Granted Designation for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy Based on Results of REDWOOD-HCM
Published: 2021-12-09 (Crawled : 13:00) - biospace.com/
CYTK | $67.49 0.73% 0.73% 1.5M
|
Health Technology
|
| O: -2.93%
H: 0.0%
C: 0.0%
treatment fda cardio granted therapy results breakthrough therapy designation
Industrial Wastewater Treatment Chemicals Market worth $16.6 billion by 2026 - Exclusive Report by MarketsandMarkets™
Published: 2021-12-09 (Crawled : 12:30) - prnewswire.com
ECL | News | $218.16 -0.48% 0.69% 2.6M
|
Process Industries
|
| O: -0.2%
H: 0.25%
C: -0.26%
DOW A | $56.66 0.3% -0.03% 3.7M
|
Process Industries
|
| O: -1.92%
H: 0.63%
C: 0.28%
treatment trial
Affimed to Host Virtual Investor Call Today to Discuss Treatment of CD30-positive Lymphoma Patients with Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13
Published: 2021-12-09 (Crawled : 12:00) - globenewswire.com
AFMD | $5.15 1.58% 1.55% 64K
|
Health Technology
|
| O: 4.4%
H: 0.44%
C: -9.16%
cd30 treatment blood positive oda
QIAGEN and Denovo Biopharma Partner to Develop Companion Diagnostic Test for the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL)
Published: 2021-12-09 (Crawled : 08:00) - biospace.com/
QGEN | $40.0 1.34% 0.0% 1.1M
|
Health Technology
|
| O: 0.82%
H: 0.29%
C: -1.35%
QGEN | $40.0 1.34% 0.0% 1.1M
|
Health Technology
|
| O: 0.82%
H: 0.29%
C: -1.35%
diagnostic treatment biopharma test t-cell
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.